NCT04004650

Brief Summary

Background: About 700 patients per year undergo an abdominoperineal resection (APR) for distal rectal cancer (Dutch Colorectal Audit 2016).Neoadjuvant (chemo)radiotherapy is often used to further improve locoregional control. Morbidity after APR is substantial and mainly consisting of perineal wound problems in about 35% of the patients. lf primary healing of the perineal wound after APR doesn't occur, secondary healing can take up to one year, and there is even a small proportion of patients in whom a chronic perineal wound or fistula persists after one year. During this long period, intensive wound care is necessary. This results in a heavy burden on both patient and health care resources. Objective: The high morbidity rate of the perineal wound has resulted in a continuing discussion on how to close the perineal defect after APR. Our research group recently published the BIOPEX-study (NL42094.018.12), in which 104 patients were randomized between primary perinea! wound closure and biological mesh closure of the pelvic floor after APR with preoperative radiotherapy for rectal cancer. Similar uncomplicated perineal wound healing rate at 30 days (Southampton wound score \< 2) was found: 63% versus 66%, respectively. The hypothesis behind this negative trial result is related to the perineal dead space between the skin and the biological mesh. Fluid will accumulate in this dead space with the risk of secondary contamination and abscess formation, leading to wound dehiscence and purulent discharge. Autologous tissue flaps have been suggested to improve perineal wound healing based on several cohort studies. At least in the Netherlands, these flaps are used only for selected patients with the large defects and highest risk of wound problems, because of the more extensive surgery with added surgical trauma and operative time, and associated donor site morbidity. For these reasons, primary perineal closure (control arm of BIOPEX) is still the standard of care in the Netherlands. A gluteal turnover flap (GT flap) is a small transposition flap trom the unilateral adjacent perineal skin and subcutaneous fat, which is flipped into the perineal dead space, and stitched with the de-epithelialised dermis to the contralateral pelvic floor remnant. Subsequently, the perineal subcutaneous fat and skin are closed over the flap in the midline, thereby not adding a donor site scar. A small pilot study trom our group showed that this is a promising solution for routine perineal closure after APR. Study design: In this multicenter single blinded study, eligible patients will be randomized between pelvic floor reconstruction using a GT flap (intervention arm) and primary closure of the perineal defect (standard arm). The perineal wound healing will be evaluated at 14 days and 1, 3, and 6 months post-operatively using the Southampton wound scoring system by an independent observer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 10, 2019

Completed
18 days until next milestone

Study Start

First participant enrolled

June 28, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 2, 2019

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2022

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2022

Completed
Last Updated

July 2, 2019

Status Verified

July 1, 2019

Enrollment Period

2.8 years

First QC Date

June 10, 2019

Last Update Submit

July 1, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Perineal wound healing rate 30 days

    The primary endpoint of the study is the percentage of uncomplicated perineal wound healing defined as a Southampton wound score of less than Il at 30 days postoperatively.

    30 days

Secondary Outcomes (10)

  • Perineal wound healing

    14 days, 3 and 6 months postoperatively

  • Re-intervention or re-admission rate

    1,3,6 months

  • Perineal hernia rate

    1,3,6 months

  • Health-related quality of life

    1,3,6 months

  • Quality of Life in cancer patients

    1,3,6 months

  • +5 more secondary outcomes

Study Arms (2)

Primary closure

NO INTERVENTION

Primary perineal closure after extralevator abdomino perineal resection

Gluteal turnover flap

EXPERIMENTAL

Gluteal flap reconstruction of the pelvic floor after extralevator abdomino perineal resection

Procedure: Gluteal turnover flap

Interventions

Link to procedure: https://www.youtube.com/watch?v=u7\_vH2\_1ZZc

Gluteal turnover flap

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • clinical diagnosis of primary rectal cancer or recurrent rectal cancer
  • scheduled for abdominalperineal resection
  • older then 18 years

You may not qualify if:

  • intersphincteric APR
  • (biological) mesh placement
  • extended resections (sacral resection except for coccyx resection, (posterior) exenteration)
  • severe systemic diseases affecting wound healing except diabetes (i.e. renal failure requiring dialysis, liver cirrhosis, and immune compromised status like HIV), collagen disorders (i.e. Marfan)
  • enrolment in other trials with overlapping primary endpoint.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Amsterdam UMC, location AMC

Amsterdam-Zuidoost, North Holland, 1105AZ, Netherlands

RECRUITING

Related Publications (2)

  • Kreisel SI, Sharabiany S, Tuynman J, Belgers EHJ, Singh B, Chaudhri S, van Geloven AAW, Vuylsteke RJCLM, de Wilt JHW, Melenhorst J, Leijtens JWA, Vermaas M, Rothbarth J, Verhoef C, Burger JWA, Polat F, Fabry HFJ, Aalbers AGJ, Wijsman JH, Lamme B, van der Bilt JDW, Lapid O, van Dieren S, Hompes R, Tanis PJ, Musters GD. Perineal Wound Closure Using Gluteal Turnover Flap After Abdominoperineal Resection for Rectal Cancer: The BIOPEX-2 Randomized Clinical Trial. JAMA Surg. 2025 Apr 1;160(4):378-385. doi: 10.1001/jamasurg.2024.6818. Erratum In: JAMA Surg. 2025 Apr 1;160(4):471. doi: 10.1001/jamasurg.2025.0523.

  • Sharabiany S, Blok RD, Lapid O, Hompes R, Bemelman WA, Alberts VP, Lamme B, Wijsman JH, Tuynman JB, Aalbers AGJ, Beets GL, Fabry HFJ, Cherepanin IM, Polat F, Burger JWA, Rutten HJT, Bosker RJI, Talsma K, Rothbarth J, Verhoef C, van de Ven AWH, van der Bilt JDW, de Graaf EJR, Doornebosch PG, Leijtens JWA, Heemskerk J, Singh B, Chaudhri S, Gerhards MF, Karsten TM, de Wilt JHW, Bremers AJA, Vuylsteke RJCLM, Heuff G, van Geloven AAW, Tanis PJ, Musters GD. Perineal wound closure using gluteal turnover flap or primary closure after abdominoperineal resection for rectal cancer: study protocol of a randomised controlled multicentre trial (BIOPEX-2 study). BMC Surg. 2020 Jul 23;20(1):164. doi: 10.1186/s12893-020-00823-7.

MeSH Terms

Conditions

Rectal Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Pieter Tanis, Prof. MD. Phd

    Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Gijsnert Musters, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD PhD, reseach coordinator

Study Record Dates

First Submitted

June 10, 2019

First Posted

July 2, 2019

Study Start

June 28, 2019

Primary Completion

May 1, 2022

Study Completion

November 1, 2022

Last Updated

July 2, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

Locations